Personalized use of disease-modifying therapies in multiple sclerosis
CY Lee, KH Chan - Pharmaceutics, 2024 - mdpi.com
Multiple sclerosis is an important neurological disease affecting millions of young patients
globally. It is encouraging that more than ten disease-modifying drugs became available for …
globally. It is encouraging that more than ten disease-modifying drugs became available for …
Ublituximab: first approval
A Lee - Drugs, 2023 - Springer
Ublituximab (ublituximab-xiiy; BRIUMVI™) is a glycoengineered anti-CD20 monoclonal
antibody developed by TG Therapeutics, Inc. for the treatment of multiple sclerosis (MS). The …
antibody developed by TG Therapeutics, Inc. for the treatment of multiple sclerosis (MS). The …
Effect of ocrelizumab on leptomeningeal inflammation and humoral response to Epstein-Barr virus in multiple sclerosis. A pilot study
Background Ocrelizumab is an effective treatment for relapsing and primary-progressive
multiple sclerosis (MS). However, the effect of ocrelizumab on leptomeningeal (LM) …
multiple sclerosis (MS). However, the effect of ocrelizumab on leptomeningeal (LM) …
Whole-blood methylation signatures are associated with and accurately classify multiple sclerosis disease severity
Background The variation in multiple sclerosis (MS) disease severity is incompletely
explained by genetics, suggesting genetic and environmental interactions are involved …
explained by genetics, suggesting genetic and environmental interactions are involved …
[HTML][HTML] Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management
E Alvarez, EE Longbrake, KW Rammohan… - Multiple Sclerosis and …, 2023 - Elsevier
Hypogammaglobulinemia is characterized by reduced serum immunoglobulin levels.
Secondary hypogammaglobulinemia is of considerable interest to the practicing physician …
Secondary hypogammaglobulinemia is of considerable interest to the practicing physician …
Epstein–Barr virus infection, B‐cell dysfunction and other risk factors converge in gut‐associated lymphoid tissue to drive the immunopathogenesis of multiple …
Multiple sclerosis is associated with Epstein–Barr virus (EBV) infection, B‐cell dysfunction,
gut dysbiosis, and environmental and genetic risk factors, including female sex. A disease …
gut dysbiosis, and environmental and genetic risk factors, including female sex. A disease …
[HTML][HTML] Does ocrelizumab limit multiple sclerosis progression? Current evidence from clinical, MRI, and fluid biomarkers
M Margoni, P Preziosa, P Tortorella, M Filippi… - …, 2022 - Elsevier
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative
disease affecting the central nervous system, often characterized by the accumulation of …
disease affecting the central nervous system, often characterized by the accumulation of …
Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment
SR Delgado, S Faissner, RA Linker, K Rammohan - Journal of neurology, 2024 - Springer
The recent success of anti-CD20 monoclonal antibody therapies in the treatment of multiple
sclerosis (MS) has highlighted the role of B cells in the pathogenesis of MS. In people with …
sclerosis (MS) has highlighted the role of B cells in the pathogenesis of MS. In people with …
The state of the art of pediatric multiple sclerosis
RI Teleanu, AG Niculescu, OA Vladacenco… - International Journal of …, 2023 - mdpi.com
Multiple sclerosis (MS) represents a chronic immune-mediated neurodegenerative disease
of the central nervous system that generally debuts around the age of 20–30 years. Still, in …
of the central nervous system that generally debuts around the age of 20–30 years. Still, in …
A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis
Background Progressive multiple sclerosis (PMS) is a debilitating condition characterized by
progressively worsening symptoms. Monoclonal antibodies are novel therapies for MS, but …
progressively worsening symptoms. Monoclonal antibodies are novel therapies for MS, but …